Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun:3:91-96.
doi: 10.1016/j.pvr.2017.03.001. Epub 2017 Mar 16.

Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002-2012

Affiliations

Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002-2012

J Skufca et al. Papillomavirus Res. 2017 Jun.

Abstract

Background: In Finland a vaccination programme against human papillomavirus (HPV) was introduced in November 2013 for girls aged 11-12 years with a catchup for girls 13-15 years. Allegations that HPV vaccine is causing Guillain Barré syndrome (GBS) and non-specific diagnostic entities, such as chronic fatigue syndrome/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS), continue to surface. We examined population register-based incidence rates of CFS/SEID, GBS and POTS to provide baseline data for future HPV vaccine safety evaluations.

Methods: First diagnosis of CFS/SEID, GBS and POTS in girls aged 11-15 years were obtained from the National Hospital Discharge Register during 2002-2012. We considered the following ICD-10 codes: G93.3 for CFS; G61.0 for GBS and G90.9, G90.8, G93.3, I49.8 for POTS. We calculated incidence rates per 100,000 person-years with 95% confidence intervals (CI).

Results: In total, 9 CFS/SEID, 19 GBS and 72 POTS cases were identified. The overall incidence rate was 0.53/100,000 (95% CI; 0.27-1.01) for CFS/SEID, 1.11 (95% CI; 0.71-1.74) for GBS and 4.21 (95%CI; 3.34-5.30) for POTS. Significant relative increase in annual incidence rate with a peak in 2012 was observed in CFS/SEID (33% (95% CI; 3.0-70.3: p=0.029) and POTS (16.5% (95% CI; 7.8-25.9: p<0.05), but not in GBS (5.4% (95% CI; -8.4-21.3: p=0.460).

Conclusions: Our findings provide baseline estimates of CFS/SEID, GBS and POTS incidences in Finland. However, rates based on register data should be interpreted with caution, especially for non-specific diagnostic entities for which internationally and even nationally agreed criteria are still being discussed. To assess the associations with HPV vaccine, methods using register linkage for cohort and self-controlled case series should be explored in addition to factors contributing to patients seeking care, treating physicians setting the diagnoses, and their preference of using of codes for these clinical entities.

Keywords: Chronic fatigue syndrome/Systemic exertion intolerance disease; Finland; Guillain Barré syndrome; Incidence rates; Papillomavirus vaccines; Postural orthostatic tachycardia syndrome; Vaccination adverse effects.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1
Average annual incidence rate of chronic fatigue syndrome/systemic exertion intolerance disease (CFS/SEID) by age groups and sex during 2002–2012 in Finland.
Fig. 2.
Fig. 2
Average annual incidence rate of Guillain Barré syndrome (GBS) by age groups and sex during 2002–2012 in Finland.
Fig. 3.
Fig. 3
Average annual incidence rate of postural orthostatic tachycardia syndrome (POTS) by age groups and sex during 2002–2012 in Finland.
Fig. 4.
Fig. 4
Chronic fatigue syndrome/systemic exertion intolerance disease (CFS/SEID), Guillain Barré syndrome (GBS) and postural orthostatic tachycardia syndrome (POTS) in girls of age 11–15 years during 2002–2012 in Finland.
Fig. 5.
Fig. 5
Annual incidence rate of chronic fatigue syndrome/systemic exertion intolerance disease (CFS/SEID), Guillain Barré syndrome (GBS) and postural orthostatic tachycardia syndrome (POTS) in girls of age 11–15 years during 2002–2012 in Finland.

References

    1. World Health Organization Human papillomavirus vaccines: WHO position paper. Wkly. Epidemiol. Rec. 2014;43(89):465–492. - PubMed
    1. Paavonen J., Jenkins D., Bosch X., Naud P., Salmeron J., Wheeler C. Efficacy of a prophylactic adjuvanted L1 VLP vaccine against infection with HPV16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial. Lancet. 2007;369:2161–2170. - PubMed
    1. Villa L., Perez G., Kjaer S., Lehtinen M., Paavonen J., Muñoz N. Efficacy of a quadrivalent HPV types 8/11/16/18) L1 virus-like particle vaccine in the prevention of cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ: a randomized controlled trial. N. Engl. J. Med. 2007;356:1915–1927. - PubMed
    1. National Institute for Health and Welfare (THL), Department of Vaccination and Immune Protection. HPV vaccination coverage in Finland; 2016 . (Accessed 11 April 2016).
    1. Finnish Medicines Agency (Fimea). Question E 9/2015 from the Nordic Council regarding adverse reactions to HPV-vaccine. Contribution from Finland to the question from the Nordic Council; 3 Nov 2015.

LinkOut - more resources